Targeted Drug Delivery for the Treatment of Abdominal Pain in Chronic Pancreatitis: A Retrospective Case Series.
abdominal pain
chronic pancreatitis
intrathecal opioid pump
intrathecal pump therapy
severe pancreatitis
targeted drug delivery
Journal
Cureus
ISSN: 2168-8184
Titre abrégé: Cureus
Pays: United States
ID NLM: 101596737
Informations de publication
Date de publication:
Mar 2024
Mar 2024
Historique:
accepted:
30
03
2024
medline:
1
5
2024
pubmed:
1
5
2024
entrez:
1
5
2024
Statut:
epublish
Résumé
Abdominal pain secondary to chronic pancreatitis (CP) is difficult to manage and often requires chronic oral opioid therapy (OOT). Targeted drug delivery (TDD) allows for a diminished dose of opioid intake and improved pain levels. TDD has been used in different pain syndromes with only limited reports in CP. The objective of this article is to perform a retrospective review of CP patients treated with TDD versus OOT to compare chronic pain control and consumed morphine-equivalent doses. Patients receiving TDD between September 2011 and August 2018 were included. All patients were weaned off oral opioids one week before intrathecal trial and pump implantation. Patients with intrathecal trials providing at least 50% pain relief underwent pump implantation. Data were collected while on OOT and at two weeks, three months, and nine months post-implant. Data were analyzed with Microsoft Excel 365 MSO using means and standard deviations. P-values were calculated using a two-tailed student's t-test with paired two-sample means. Twenty-three patients were analyzed. Pre-trial average pain score was 6.5/10 with a mean improvement with trials greater than 71%. The mean chronic baseline oral morphine milligram equivalents (MME) was 188. The mean MME on TDD at two weeks (0.36), three months (1.39), and nine months (2.47) were significantly lower than OOT. Mean pain scores were 6, 4.9, and 5.6 at two weeks, three months, and nine months, respectively, compared to 6.5 on OOT. The results of this study indicate that TDD provides improved pain control with significantly lower opioid doses.
Identifiants
pubmed: 38690495
doi: 10.7759/cureus.57285
pmc: PMC11058739
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e57285Informations de copyright
Copyright © 2024, Cooper et al.
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.